https://doi.org/10.4081/hmr.v2i5.756

J-L. Harousseau Tipifarnib in hematologic malignancies

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 153
PDF: 231
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

JL Harousseau
support@pagepress.org
Farnesyltranferase inhibitors (FTI) are signal transduction inhibitors that block farnesylation of a number of proteins including Ras that are involved in key cellular functions (proliferation,survival and differentiation).1,2 Tipifarnib is a potent inhibitor of farnesyltransferase that is orally bioavailable. Tipifarnib was initially developed with the goal of targeting Ras in cancers with a high incidence of Ras mutations. However, after failure of large clinical trials in solid tumors (pancreas, colon) further development was mainly focused on hematologic malignancies

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Harousseau, J. (2009). J-L. Harousseau Tipifarnib in hematologic malignancies. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.756
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).